EUVIMEDEUVIMED entdecken
Crossref

In vitro and in vivo evaluation of DNase I in reinstating antibiotic efficacy against Klebsiella pneumoniae biofilms

Anayata Sharma, Praveen Rishi iD, Rachna Singh iD

Pathogens and Disease · 2023

DOI: 10.1093/femspd/ftad001 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pathogens and Disease, 2023. Verfasst von Anayata Sharma und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbial Biotechnology, Panjab University, Chandigarh, 160014, India. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Klebsiella pneumoniae. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Senior Research Fellowship, CMB, BMS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Klebsiella pneumoniae is an opportunistic pathogen associated with biofilm-based infections, which are intrinsically antibiotic resistant. Extracellular DNA plays a crucial role in biofilm formation and self-defence, with nucleases being proposed as promising agents for biofilm disruption. This study evaluated the in vitro and in vivo efficacy of DNase I in improving the activity of cefotaxime, amikacin, and ciprofloxacin against K. pneumoniae biofilms. K. pneumoniae ATCC 700603 and a clinical isolate from catheter-related bloodstream infection were cultured for biofilm formation on microtiter plates, and the antibiofilm activity of the antibiotics (0.03–64 mg/L), with or without bovine pancreatic DNase I (1–32 mg/L) was determined by XTT dye reduction test and viable counting. The effect of ciprofloxacin (2 mg/L) and DNase I (16 mg/L) was further evaluated in vitro on 1-cm-long silicon catheter segments, and in a mouse model of subcutaneous catheter-associated infection. Combination with DNase I did not improve the biofilm-preventive capacity of the three antibiotics or the biofilm-eradicating capacity of cefotaxime and amikacin. The biofilm-eradicating capacity of ciprofloxacin was increased by 8-fold and 4-fold in K. pneumoniae ATCC 700603 and clinical isolate, respectively, with DNase I. The combination therapy caused 99% reduction in biofilm biomass in the mouse model.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsKlebsiella pneumoniaeMiceAnimalsCattleAmikacinDeoxyribonuclease IMicrobial Sensitivity TestsCiprofloxacinBiofilmsDisease Models, AnimalCefotaxime

Stichwörter der Autor:innen

Klebsiella pneumoniaeDNase Iantibioticsbiofilmcathetereradication

Substanzen

Anti-Bacterial AgentsAmikacinDeoxyribonuclease ICiprofloxacinCefotaxime

Autor:innen und Institutionen

  • Department of Microbial Biotechnology, Panjab University, Chandigarh, 160014, India.
  • Department of Microbiology, Panjab University, Chandigarh, 160014, India.

ORCID-Profile: Praveen Rishi, Rachna Singh

Förderung

  • Senior Research Fellowship
  • CMB
  • BMS
  • Indian Council of Medical Research
  • Department of Science and Technology
  • DST

Zitieren

APA

Sharma, A., Rishi, P., & Singh, R. (2023). In vitro and in vivo evaluation of DNase I in reinstating antibiotic efficacy against Klebsiella pneumoniae biofilms. Pathogens and Disease. https://doi.org/10.1093/femspd/ftad001

Vancouver

Sharma A, Rishi P, Singh R. In vitro and in vivo evaluation of DNase I in reinstating antibiotic efficacy against Klebsiella pneumoniae biofilms. Pathogens and Disease. 2023. doi:10.1093/femspd/ftad001

BibTeX
@article{Sharma2023,
  author = {Sharma, Anayata and Rishi, Praveen and Singh, Rachna},
  title = {In vitro and in vivo evaluation of DNase I in reinstating antibiotic efficacy against Klebsiella pneumoniae biofilms},
  journal = {Pathogens and Disease},
  year = {2023},
  doi = {10.1093/femspd/ftad001}
}
Kostenlos starten →